Hypothesized role of pregnancy hormones on HER2+ breast tumor development

Breast Cancer Research and Treatment

Volumn 137, Issue 1, 2013, Pages 237-246

  Cruz, Giovanna I ^a   Martínez, María Elena ^b   Natarajan, Loki ^b   Wertheim, Betsy C ^c   Gago Dominguez, Manuela ^d   Bondy, Melissa ^e   Daneri Navarro, Adrian ^f   Meza Montenegro, María Mercedes ^g   Gutierrez Millan, Luis Enrique ^h   Brewster, Abenaa ⁱ   Schedin, Pepper ^j   Komenaka, Ian K ^k   Castelao, J Esteban ^l   Carracedo, Angel ^d   Redondo, Carmen M ^l   Thompson, Patricia A ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF GUADALAJARA   (Mexico)

^g INSTITUTO TECNOLÓGICO DE SONORA   (Mexico)

^h UNIVERSIDAD DE SONORA   (Mexico)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k MARICOPA MEDICAL CENTER   (United States)

^l UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^m UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Breast cancer; Breast tumor subtypes; Etiologic heterogeneity; HER2; Hispanic; Parity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER LOCALIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GESTATION PERIOD; HISPANIC; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MEXICO; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RISK FACTOR; SIGNAL TRANSDUCTION; SPAIN; UNITED STATES;

ADULT; BREAST NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HISPANIC AMERICANS; HUMANS; INCIDENCE; LOGISTIC MODELS; MEXICO; MIDDLE AGED; PLACENTAL HORMONES; PREGNANCY; PREMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SPAIN; UNITED STATES; YOUNG ADULT;

EID: 84871735036     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2313-0     Document Type: Article

References (50)

1. Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100(22):1643-1648. doi: 10.1093/jnci/djn344
2. DeSantis C, Howlader N, Cronin KA, Jemal A (2011) A Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20(5):733-739. doi: 10.1158/1055-9965.EPI-11-0061
3. Martinez ME, Nielson CM, Nagle R, Lopez AM, Kim C, Thompson P (2007) Breast cancer among Hispanic and non-Hispanic White women in Arizona. J Health Care Poor Underserved 18(4 Suppl):130-145. doi: 10.1353/hpu.2007.0112
4. Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86(9):705-712
5. Hedeen AN, White E (2001) Breast cancer size and stage in Hispanic American women, by birthplace: 1992-1995. Am J Public Health 91(1):122-125
6. Rodriguez-Cuevas S, Macias CG, Franceschi D, Labastida S (2001) Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 91(4):863-868. doi: 10.1002/1097- 0142(20010215)91:4<863:AID-CNCR1074>3.0.CO;2-Y
7. Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163(1):49-56
8. Sorlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40(18):2667-2675. doi: 10.1016/j.ejca.2004.08.021
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752. doi: 10.1038/35021093
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874. doi: 10.1073/pnas.19136709898/19/ 10869
11. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502. doi: 10.1001/jama.295.21.2492
12. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071-1082. doi: 10.1007/s10552-009-9331-1
13. Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 15(6):593-602. doi: 10.1111/j.1524-4741.2009.00822.x
14. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123-139. doi: 10.1007/s10549-007-9632-6
15. Martinez ME, Cruz GI, Brewster AM, Bondy ML, Thompson PA (2010) What can we learn about disease etiology from case-case analyses? Lessons from breast cancer. Cancer Epidemiol Biomarkers Prev 19(11):2710-2714. doi: 10.1158/1055-9965.EPI-10-0742
16. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558-1568
17. Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86(5):723-727. doi: 10.1038/sj.bjc.6600124
18. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L (2003) Dual effect of parity on breast cancer risk in African-American women. J Natl Cancer Inst 95(6):478-483
19. Pathak DR, Osuch JR, He J (2000) Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 88(5 Suppl):1230-1238. doi: 10.1002/(SICI)1097-0142(20000301)88:5+<1230:AID-CNCR9>3.0.CO;2-F
20. Albrektsen G, Heuch I, Kvale G (1995) The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer 72(2):480-484
21. Albrektsen G, Heuch I, Hansen S, Kvale G (2005) Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer 92(1):167-175. doi: 10.1038/sj.bjc.6602302
22. Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 13(4):299-305
23. Lethaby AE, O'Neill MA, Mason BH, Holdaway IM, Harvey VJ (1996) Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer 67(6):751-755. doi: 10.1002/(SICI)1097-0215(19960917)67:6<751:AID-IJC1>3.0.CO;2-Q
24. Kroman N, Mouridsen HT (2003) Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. Breast 12(6):516-521
25. Lyons TR, Schedin PJ, Borges VF (2009) Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia 14(2):87-98. doi: 10.1007/s10911-009-9119-7
26. Borges VF, Schedin PJ (2012) Pregnancy-associated breast cancer: an entity needing refinement of the definition. Cancer 118(13):3226-3228. doi: 10.1002/cncr.26643
27. Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Diaz Flaque MC, Charreau EH, Schillaci R, Elizalde PV (2009) Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 29(5):1249-1265. doi: 10.1128/MCB.00853-08
28. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB (1998) Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273(47):31317-31326
29. Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD (2009) Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res 7(11):1882-1892. doi: 10.1158/1541-7786.mcr-08-0509
30. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31. doi: 10.1186/bcr2261
31. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML (2011) Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS ONE 6(8):e23543. doi: 10.1371/journal.pone.0023543
32. Sutton P, Hamilton, BE, Mathews, TJ (2011) Recent decline in births in the United States, 2007-2009. NCHS Data Brief No. 60. National Center for Health Statistics, Hyattsville
33. Martinez ME et al (2010) Comparative study of breast cancer in Mexican and Mexican-American women. Health 2(9):1040-1048. doi: 10.4236/health.2010. 29153
34. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795. doi: 10.1200/jco.2009.25.6529
35. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2006) American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145. doi: 10.1200/jco.2006.09.2775
36. Bladstrom A, Anderson H, Olsson H (2003) Worse survival in breast cancer among women with recent childbirth: results from a Swedish population-based register study. Clin Breast Cancer 4(4):280-285
37. Olson SH, Zauber AG, Tang J, Harlap S (1998) Relation of time since last birth and parity to survival of young women with breast cancer. Epidemiology 9(6):669-671
38. Hedges LV, Vevea JL (1998) Fixed- and random-effects models in meta-analysis. Psychol Methods 3(4):486-504
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560. doi: 10.1136/bmj.327. 7414.557
40. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W, Bernstein JL (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130(2):587-597. doi: 10.1007/s10549-011-1616-x
41. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113(7):1521-1526. doi: 10.1002/cncr.23786
42. Xing P, Li J, Jin F (2010) A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 27(3):926-931. doi: 10.1007/s12032-009-9308-7
43. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI (2011) Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 22(3):399-405. doi: 10.1007/s10552-010-9709-0
44. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, Press MF, Bernstein L (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 70(2):575-587. doi: 10.1158/0008-5472.CAN-09-3460
45. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439-443. doi: 10.1158/1055-9965.EPI-06-0806
46. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC (2012) Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131(1):159-167. doi: 10.1007/s10549-011-1702-0
47. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL (2002) The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 11(3):235-241
48. Pilewskie M, Gorodinsky P, Fought A, Hansen N, Bethke K, Jeruss J, Scholtens D, Khan SA (2012) Association between recency of last pregnancy and biologic subtype of breast cancer. Ann Surg Oncol 19(4):1167-1173. doi: 10.1245/s10434-011-2104-6
49. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10(4):R67. doi: 10.1186/bcr2128
50. Bhargava R, Dabbs DJ (2008) Luminal B breast tumors are not HER2 positive. Breast Cancer Res 10(5):404. doi: 10.1186/bcr2134 author reply 405